Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study.

Arnulf Stenzl,Curtis Dunshee,Ugo De Giorgi,Boris Alekseev,Taro Iguchi,Russell Z. Szmulewitz,Thomas W. Flaig,Bertrand F. Tombal,Robert Morlock,Cristina Ivanescu,Krishnan Ramaswamy,Fred Saad,Andrew J. Armstrong

Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study.

2019

Arnulf Stenzl
Curtis Dunshee
Ugo De Giorgi
Boris Alekseev
Taro Iguchi
Russell Z. Szmulewitz
Thomas W. Flaig
Bertrand F. Tombal
Robert Morlock
Cristina Ivanescu
Krishnan Ramaswamy
Fred Saad
Andrew J. Armstrong

5044Background: The Phase 3 ARCHES trial (NCT02677896) evaluated the efficacy and safety of ENZ + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT in 1150 men with mHSPC. Here we report pa...

Keywords:

Hormone sensitive prostate cancer
Physical therapy
Oncology
Quality of life
Enzalutamide
Medicine
Internal medicine
Placebo
Androgen deprivation therapy
health related quality of life

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations